Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents.

Kashyap T, Argueta C, Unger T, Klebanov B, Debler S, Senapedis W, Crochiere ML, Lee MS, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2018 Jul 20;9(56):30773-30786. doi: 10.18632/oncotarget.25637. eCollection 2018 Jul 20.

2.

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.

Argueta C, Kashyap T, Klebanov B, Unger TJ, Guo C, Harrington S, Baloglu E, Lee M, Senapedis W, Shacham S, Landesman Y.

Oncotarget. 2018 May 22;9(39):25529-25544. doi: 10.18632/oncotarget.25368. eCollection 2018 May 22.

3.

Utility-Value Score: A Case Study in System Generalization for Writing Analytics.

Klebanov BB, Priniski S, Burstein J, Gyawali B, Harackiewicz J, Thoman D.

J Writ Anal. 2018;2:314-328.

4.

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.

Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, Crochiere M, Italiano JE Jr, Landesman Y.

Blood. 2017 Aug 31;130(9):1132-1143. doi: 10.1182/blood-2016-11-752840. Epub 2017 Jun 19.

5.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R.

Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23.

6.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

7.

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.

Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, Landesman Y, Dougan M, Dougan SK.

Mol Cancer Ther. 2017 Mar;16(3):428-439. doi: 10.1158/1535-7163.MCT-16-0496. Epub 2017 Feb 1.

8.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

9.

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere ML, Baloglu E, Klebanov B, Donovan S, Del Alamo D, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Jan 12;7(2):1863-77. doi: 10.18632/oncotarget.6495.

10.

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere M, Kashyap T, Kalid O, Shechter S, Klebanov B, Senapedis W, Saint-Martin JR, Landesman Y.

BMC Cancer. 2015 Nov 17;15:910. doi: 10.1186/s12885-015-1790-z.

11.

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.

Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT.

Leukemia. 2016 Jan;30(1):190-9. doi: 10.1038/leu.2015.194. Epub 2015 Jul 23.

12.

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.

Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, Fenton OS, Zhang Y, Olejnik KT, Yesilyurt V, Chen D, Barros S, Klebanov B, Novobrantseva T, Langer R, Anderson DG.

Nat Commun. 2014 Jun 27;5:4277. doi: 10.1038/ncomms5277.

13.

In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing.

Courties G, Heidt T, Sebas M, Iwamoto Y, Jeon D, Truelove J, Tricot B, Wojtkiewicz G, Dutta P, Sager HB, Borodovsky A, Novobrantseva T, Klebanov B, Fitzgerald K, Anderson DG, Libby P, Swirski FK, Weissleder R, Nahrendorf M.

J Am Coll Cardiol. 2014 Apr 22;63(15):1556-66. doi: 10.1016/j.jacc.2013.11.023. Epub 2013 Dec 18.

14.

Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells.

Novobrantseva TI, Borodovsky A, Wong J, Klebanov B, Zafari M, Yucius K, Querbes W, Ge P, Ruda VM, Milstein S, Speciner L, Duncan R, Barros S, Basha G, Cullis P, Akinc A, Donahoe JS, Narayanannair Jayaprakash K, Jayaraman M, Bogorad RL, Love K, Whitehead K, Levins C, Manoharan M, Swirski FK, Weissleder R, Langer R, Anderson DG, de Fougerolles A, Nahrendorf M, Koteliansky V.

Mol Ther Nucleic Acids. 2012 Jan 24;1:e4. doi: 10.1038/mtna.2011.3.

15.

Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.

Basha G, Novobrantseva TI, Rosin N, Tam YY, Hafez IM, Wong MK, Sugo T, Ruda VM, Qin J, Klebanov B, Ciufolini M, Akinc A, Tam YK, Hope MJ, Cullis PR.

Mol Ther. 2011 Dec;19(12):2186-200. doi: 10.1038/mt.2011.190. Epub 2011 Oct 4.

16.

Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes.

Lukashev D, Klebanov B, Kojima H, Grinberg A, Ohta A, Berenfeld L, Wenger RH, Ohta A, Sitkovsky M.

J Immunol. 2006 Oct 15;177(8):4962-5.

17.

Vasorelaxation by new hybrid compounds containing dihydropyridine and pinacidil-like moieties.

Yagupolskii LM, Antepohl W, Artunc F, Handrock R, Klebanov BM, Maletina II, Marxen B, Petko KI, Quast U, Vogt A, Weiss C, Zibold J, Herzig S.

J Med Chem. 1999 Dec 16;42(25):5266-71.

PMID:
10602711
18.

[The effect of membrane channel agonists and antagonists on hemodynamics and vascular tonus].

Shevchuk VH, Iahupol's'kyĭ LM, Shavaran SS, Klebanov BM, Zyma SV.

Fiziol Zh. 1999;45(1-2):35-9. Ukrainian.

PMID:
10202634
19.

[The pharmacological regulation of inflammation: the current problems and developmental outlook].

Klebanov BM.

Eksp Klin Farmakol. 1992 Jul-Aug;55(4):4-8. Review. Russian.

PMID:
1458187
20.

[Comparative characteristics of the interaction of several nonsteroidal anti-inflammatory agents with biomembranes in experimental inflammation].

Mogilevich SE, Kul'chitskiĭ AG, Volovik ZN, Sapotiuk MV, Klebanov BM.

Farmakol Toksikol. 1989 Jul-Aug;52(4):59-61. Russian.

PMID:
2806531
21.

[Pharmacokinetics of ethonium administered perorally].

Mogilevich SE, Galushko SV, Klebanov BM.

Farmakol Toksikol. 1987 Mar-Apr;50(2):82-4. Russian.

PMID:
3582639
22.

[Program-objective method of planning in pharmacology].

Trinus FP, Klebanov BM.

Farmakol Toksikol. 1983 Sep-Oct;46(5):10-4. Russian. No abstract available.

PMID:
6354743
23.

[Effect of nonsteroid anti-inflammatory agents on the formation and metabolism of granulation-fibrous tissue in foci of inflammation].

Klebanov BM.

Farmakol Toksikol. 1981 Sep-Oct;44(5):616-9. Russian. No abstract available.

PMID:
7308445
24.

[Effect of nonsteroid anti-inflammatory substances on mediators of inflammation].

Klebanov BM.

Farmakol Toksikol. 1979 Jan-Feb;42(1):43-7. Russian.

PMID:
421890
25.

[Effect of non-steroid anti-inflammatory agents on components of the kinin system in animals with experimental inflammation].

Klebanov BM, Chernoshtan KA.

Farmakol Toksikol. 1977 Jul-Aug;40(4):428-30. Russian.

PMID:
198245
26.

[Influence of energy metabolism inhibitors on the development of experimental inflammation].

Klebanov BM.

Patol Fiziol Eksp Ter. 1977 Mar-Apr;(2):70-1. Russian. No abstract available.

PMID:
882279
27.

[Search for nonsteroidal anti-inflammatory substances among the amides of nicotinic and isonicotinic acids].

Riabukha TK, Klebanov BM, Get'man GO, Molochinskaia RI.

Farm Zh. 1976 Jan-Feb;31(1):64-5. Ukrainian. No abstract available.

PMID:
1269724
28.

[Biochemical mechanisms of the action of non-steroid anti-inflammatory agents (literature review)].

Trinus FP, Klebanov BM.

Farmakol Toksikol. 1972;35(1):112-7. Review. Russian. No abstract available.

PMID:
4401745
29.

[Derivatives of para-chlorphenoxyisobutyric acid as hypocholesteremic agents].

Klebanov BM.

Farmakol Toksikol. 1970 May-Jun;33(3):324-7. Russian. No abstract available.

PMID:
5453029
30.

[Method of primary selection of hypocholesterinemic agents (modelling endogenous hypercholesterinemia in animals)].

Klebanov BM.

Biull Eksp Biol Med. 1969 Oct;68(10):119-21. Russian. No abstract available.

PMID:
5399846
31.

[Cholesterine synthesis as an object of the action of drugs. (Review of the literature)].

Cherkes AI, Klebanov BM.

Farmakol Toksikol. 1966 Nov-Dec;29(6):751-7. Russian. No abstract available.

PMID:
6000378
32.

[PHARMACOLOGICAL STUDIES ON THE PREPARATION "NICATOL"].

KLEBANOV BM.

Farm Zh. 1963;18:48-51. Ukrainian. No abstract available.

PMID:
14149829

Supplemental Content

Loading ...
Support Center